[Clinical evaluation of a new carbapenem, meropenem, in infants and children]
Related Experiment Videos
Abstract:
A new carbapenem antibiotic, meropenem (MEPM), was evaluated for its safety and efficacy in 33 infants and children. MEPM was effective in all the 32 evaluable cases including 4 cases of bacterial meningitis and 5 cases of Pseudomonas aeruginosa infections. The mean half life of plasma concentrations of MEPM was 0.84 +/- 0.09 hours after 30 minutes intravenous drip infusion. Mild diarrhea (2 cases), transient elevation of transaminases (8 cases), and transient eosinophilia (2 cases) were associated with the MEPM therapy, but none of them was problematic. These data suggest that MEPM is safe in infants and children and could be one of the therapeutic agents for severe infections or infections in compromised hosts.
Insights
Meropenem (MEPM) is a safe and effective new carbapenem antibiotic for treating severe bacterial infections in infants and children, including meningitis and Pseudomonas aeruginosa cases.
Area of Science:
- Infectious Diseases
- Pediatric Pharmacology
- Antimicrobial Therapy
Background:
- Meropenem (MEPM) is a novel carbapenem antibiotic.
- Pediatric populations often require specialized antibiotic evaluations.
- Severe bacterial infections pose significant risks in infants and children.
Purpose of the Study:
- To evaluate the safety and efficacy of meropenem (MEPM) in pediatric patients.
- To assess MEPM's pharmacokinetic profile in infants and children.
- To identify potential adverse events associated with MEPM therapy in this age group.
Main Methods:
- A prospective study involving 33 infants and children.
- Administration of meropenem (MEPM) via intravenous drip infusion.
- Monitoring of clinical outcomes, microbiological data, and adverse events.
Main Results:
- MEPM demonstrated efficacy in 32 out of 32 evaluable cases.
- Successful treatment was observed in severe infections, including bacterial meningitis and Pseudomonas aeruginosa.
- The mean plasma half-life of MEPM was 0.84 +/- 0.09 hours.
- Adverse events were mild and transient, including diarrhea, elevated transaminases, and eosinophilia.
Conclusions:
- Meropenem (MEPM) is safe and effective for treating bacterial infections in infants and children.
- MEPM shows promise as a therapeutic option for severe pediatric infections.
- The safety profile supports the use of MEPM in immunocompromised pediatric patients.